Treatment of bipolar disorder
View Patent ↗The invention relates to sulphur- and/or selenium-containing compounds that can inhibit the enzyme inositol mono-phosphatase (IMPase), and which can be used in treating conditions that are treatable through inhibition of this enzyme, such as bi-polar disorder, the compounds having a structure of Formula (I), or is a pharmaceutically acceptable salt thereof; Formula (I); in which: E is S or Se and each of phenyl rings A and B is optionally substituted with one or more substituents, in which each substituent is selected independently from: (1) a halogen, which is preferably selected from F, Cl and Br; (2) C 1 -C 4 alkyl, such as C 1 -C 2 alkyl or C 1 alkyl, optionally substituted with one or more halogen atoms, each of which is preferably selected from F, Cl and Br; and (3) C 1 -C 4 alkoxy, such as C 1 -C 2 alkoxy or C 1 alkoxy; optionally substituted with one or more halogen atoms, each of which is preferably selected from F, Cl and Br.
1. A method of treating bipolar disorder, wherein said method comprises administering to a patient in need thereof a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein Formula I is:
in which:
E is S or Se
and each of phenyl rings A and B is optionally substituted with one or more substituents, in which each substituent is selected independently from:
(1) a halogen;
(2) C 1 -C 4 alkyl, optionally substituted with one or more halogen atoms; and
(3) C 1 -C 4 alkoxy, optionally substituted with one or more halogen atoms.
2. The method of claim 1 , wherein the amount of the compound of Formula I or pharmaceutically acceptable salt thereof administered to the patient is in the range of from 10 to 2000 mg per day.
3. The method of claim 2 , in which the compound of Formula I, or pharmaceutically acceptable salt thereof, is provided in one or more than one dose per day.
4. The method according to claim 1 , wherein the compound of Formula I, or pharmaceutically acceptable salt thereof, is administered in combination with one or more further compounds that are effective for treating bipolar disorder.
5. The method according to claim 4 , wherein said one or more further compounds are selected from the group consisting of valproic acid, lamotrigine, carbamazapine, pharmaceutically acceptable salts of one or more thereof, pharmaceutically acceptable salts of lithium, and combinations thereof.
6. The method according to claim 4 , wherein the compound of Formula I and said one or more further compounds are administered simultaneously, sequentially or separately.
7. The method as claimed in claim 1 , wherein said compound is selected from the group consisting of
8. The method as claimed in claim 7 , wherein said compound is ebselen.
9. The method according to claim 1 , wherein said halogen in (1) is selected from the group consisting of F, Cl and Br.
10. The method according to claim 1 , wherein said C 1 -C 4 alkyl is C 1 -C 2 alkyl or C 1 alkyl.
11. The method according to claim , wherein said C 1 -C 4 alkoxy is C 1 -C 2 alkoxy or C 1 alkoxy.
12. The method according to claim 1 , wherein said one or more halogen atoms in (2) or (3) is selected from the group consisting of F, Cl, and Br.
13. The method according to claim 2 , wherein said amount of the compound of Formula I or pharmaceutically acceptable salt thereof is in the range of from 10 to 300 mg per day.
14. The method according to claim 3 , wherein said compound of Formula I or pharmaceutically acceptable salt thereof is provided in two or three doses per day.